JP2021512652A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021512652A5 JP2021512652A5 JP2020565006A JP2020565006A JP2021512652A5 JP 2021512652 A5 JP2021512652 A5 JP 2021512652A5 JP 2020565006 A JP2020565006 A JP 2020565006A JP 2020565006 A JP2020565006 A JP 2020565006A JP 2021512652 A5 JP2021512652 A5 JP 2021512652A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- seq
- antigen
- binding fragment
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810144817.4A CN110144008B (zh) | 2018-02-12 | 2018-02-12 | Cd38蛋白抗体及其应用 |
| CN201810144817.4 | 2018-02-12 | ||
| PCT/CN2019/074806 WO2019154421A1 (zh) | 2018-02-12 | 2019-02-11 | Cd38蛋白抗体及其应用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021512652A JP2021512652A (ja) | 2021-05-20 |
| JP2021512652A5 true JP2021512652A5 (enExample) | 2021-07-01 |
| JP7333523B2 JP7333523B2 (ja) | 2023-08-25 |
Family
ID=67547850
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020565006A Active JP7333523B2 (ja) | 2018-02-12 | 2019-02-11 | Ｃｄ３８タンパク質抗体及びその使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US11713357B2 (enExample) |
| EP (1) | EP3753955A4 (enExample) |
| JP (1) | JP7333523B2 (enExample) |
| KR (1) | KR102770962B1 (enExample) |
| CN (3) | CN110144008B (enExample) |
| AU (1) | AU2019218518B2 (enExample) |
| BR (1) | BR112020016271A2 (enExample) |
| CA (1) | CA3091492C (enExample) |
| SG (1) | SG11202007443XA (enExample) |
| TW (1) | TWI818952B (enExample) |
| WO (1) | WO2019154421A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111303293B (zh) * | 2018-11-14 | 2022-08-30 | 杭州尚健生物技术有限公司 | 一种融合蛋白及其用途 |
| CN112876563B (zh) * | 2019-11-29 | 2022-08-16 | 康诺亚生物医药科技（成都）有限公司 | 药物组合物及其制备方法和应用 |
| CN114075283A (zh) | 2020-08-12 | 2022-02-22 | 三生国健药业（上海）股份有限公司 | 结合人cd38的抗体、其制备方法和用途 |
| CN114075285B (zh) * | 2020-08-20 | 2023-05-30 | 瑞阳(苏州)生物科技有限公司 | 抗人cd38人源化单克隆抗体及其应用 |
| CN116547307A (zh) * | 2021-12-03 | 2023-08-04 | 南京维立志博生物科技有限公司 | 结合cd38的抗体及其用途 |
| CN120769752A (zh) * | 2023-03-09 | 2025-10-10 | 无锡诺宇医药科技有限公司 | 放射性标记的抗体缀合物及其用途 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| NZ548990A (en) * | 2004-02-06 | 2009-06-26 | Morphosys Ag | Anti-CD38 human antibodies and uses therefor |
| RU2402568C2 (ru) | 2004-02-06 | 2010-10-27 | МорфоСис АГ | Человеческие анти-cd38-антитела и их применение |
| EP3312196B1 (en) | 2005-03-23 | 2019-07-17 | Genmab A/S | Antibodies against cd38 for treatment of multiple myeloma |
| KR20150139636A (ko) | 2005-10-12 | 2015-12-11 | 모르포시스 아게 | 인간 ｃｄ38에 특이적인 완전 인간 ｈｕｃａｌ ｇｏｌｄ-유도 치료 항체들의 생성 및 프로파일링 |
| EP1914242A1 (en) * | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
| US20100233176A1 (en) * | 2008-10-06 | 2010-09-16 | Cashman Neil R | Methods and systems for predicting misfolded protein epitopes |
| JOP20210044A1 (ar) * | 2010-12-30 | 2017-06-16 | Takeda Pharmaceuticals Co | الأجسام المضادة لـ cd38 |
| PL3294769T3 (pl) * | 2015-05-13 | 2021-07-05 | Morphosys Ag | Leczenie szpiczaka mnogiego (mm) |
| BR112017024877A2 (pt) | 2015-05-20 | 2019-09-17 | Janssen Biotech, Inc. | anticorpo anti-cd38 e seu uso no tratamento de amiloidose de cadeia leve e outras malignidades hematológicas positivas para cd38 |
| MD3827845T2 (ro) * | 2015-11-03 | 2022-09-30 | Janssen Biotech Inc | Formulări subcutanate de anticorpi anti-CD38 și utilizări ale acestora |
| EP3635002A1 (en) * | 2017-06-08 | 2020-04-15 | Black Belt Therapeutics Limited | Cd38 modulating antibody |
| EP3635001A1 (en) * | 2017-06-08 | 2020-04-15 | Black Belt Therapeutics Limited | Cd38 modulating antibody |
-
2018
- 2018-02-12 CN CN201810144817.4A patent/CN110144008B/zh active Active
-
2019
- 2019-02-11 BR BR112020016271-0A patent/BR112020016271A2/pt unknown
- 2019-02-11 US US16/968,994 patent/US11713357B2/en active Active
- 2019-02-11 AU AU2019218518A patent/AU2019218518B2/en active Active
- 2019-02-11 EP EP19751277.5A patent/EP3753955A4/en active Pending
- 2019-02-11 JP JP2020565006A patent/JP7333523B2/ja active Active
- 2019-02-11 TW TW108104450A patent/TWI818952B/zh active
- 2019-02-11 SG SG11202007443XA patent/SG11202007443XA/en unknown
- 2019-02-11 CN CN202210259987.3A patent/CN114835809A/zh active Pending
- 2019-02-11 CN CN201980012880.5A patent/CN111712521B/zh active Active
- 2019-02-11 CA CA3091492A patent/CA3091492C/en active Active
- 2019-02-11 KR KR1020207026216A patent/KR102770962B1/ko active Active
- 2019-02-11 WO PCT/CN2019/074806 patent/WO2019154421A1/zh not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021512652A5 (enExample) | ||
| TWI769537B (zh) | 標靶ｂｃｍａ的抗體、雙專一性抗體及其用途 | |
| IL276830B1 (en) | Anti-claudin 18.2 antibodies and their uses | |
| JP2020528750A5 (enExample) | ||
| JP2020510422A5 (enExample) | ||
| JP2017535257A5 (enExample) | ||
| JP2017149720A5 (enExample) | ||
| JP2021500916A5 (enExample) | ||
| JPWO2019173291A5 (enExample) | ||
| RU2018119165A (ru) | Антитело против лиганда 1 запрограммированной гибели клеток (pd-l1), его антигенсвязывающий фрагмент и их медицинское применение | |
| IL259036A (en) | asct2-specific binding molecules and their uses | |
| JP2015535828A5 (enExample) | ||
| CN112513094A (zh) | 结合人her2的抗体、其制备方法和用途 | |
| JP2020522280A5 (enExample) | ||
| JP2017512759A5 (enExample) | ||
| JPWO2019224711A5 (enExample) | ||
| RU2012103212A (ru) | Tlr3 связывающие агенты | |
| CN111712521A (zh) | Cd38蛋白抗体及其应用 | |
| JP2020522281A5 (enExample) | ||
| RU2017114968A (ru) | Связывающие молекулы, а именно антитела, способные связываться с l1cam (cd171) | |
| JP2019534892A5 (enExample) | ||
| JP2020515277A5 (enExample) | ||
| JPWO2022256563A5 (enExample) | ||
| RU2017123022A (ru) | Гуманизованные антитела, специфичные к альфа-энолазе, и способы применения в противоопухолевой тарапии | |
| IL278323B2 (en) | Antibodies directed against glycoprotein IV |